Ixekizumab + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis
Conditions
Psoriasis
Trial Timeline
Apr 1, 2010 → Jul 1, 2016
NCT ID
NCT01107457About Ixekizumab + Placebo
Ixekizumab + Placebo is a phase 2 stage product being developed by Eli Lilly for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01107457. Target conditions include Psoriasis.
What happened to similar drugs?
20 of 20 similar drugs in Psoriasis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04285229 | Phase 3 | Completed |
| NCT03364309 | Phase 3 | Completed |
| NCT03129100 | Phase 3 | Completed |
| NCT02757352 | Phase 3 | Completed |
| NCT02696798 | Phase 3 | Completed |
| NCT02718898 | Phase 3 | Completed |
| NCT02584855 | Phase 3 | Completed |
| NCT02513550 | Phase 3 | Completed |
| NCT01107457 | Phase 2 | Completed |
Competing Products
20 competing products in Psoriasis